Also, non-radiolabeled “cold” CXCR4 antagonists such as Plerixafor may have a role in decreasing tumor proliferation in patients demonstrating CXCR4 expression in PET/CT imaging [51,52]. Here, CXCR4 is linked to neoplasm.